GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CANbridge Pharmaceuticals 1228.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

1.69

+2.42%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥50.0m

FY2014FY2025

Net income

CN¥14.8m

FY2014FY2025

Free cash flow

−CN¥38.2m

FY2014FY2025

Shareholders' equity

−CN¥341.9m

FY2014FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2014
RevenueCN¥50.0mCN¥72.8mCN¥102.9mCN¥67.5mCN¥31.2mCN¥12.0mCN¥360.1m
Gross profitCN¥36.6mCN¥46.4mCN¥64.2mCN¥41.8mCN¥18.8mCN¥6.9m—
Research and developmentCN¥45.1mCN¥215.3mCN¥257.2mCN¥266.1mCN¥427.7mCN¥109.6m—
Operating income−CN¥92.7m−CN¥291.2m−CN¥366.5m−CN¥410.9m−CN¥655.1m−CN¥842.2m—
Net incomeCN¥14.8m−CN¥378.5m−CN¥378.8m−CN¥413.4m−CN¥1.08bn−CN¥846.0m—
Diluted earnings per share0.03-0.89-0.89-0.97-9.37-12.32—

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2014
Total assetsCN¥165.5mCN¥116.8mCN¥395.4mCN¥702.0mCN¥892.5mCN¥586.4mCN¥4.80bn
Cash and short-term investmentsCN¥66.7mCN¥10.5mCN¥137.5mCN¥451.2mCN¥745.8mCN¥360.8m—
Total liabilitiesCN¥507.4mCN¥591.3mCN¥435.1mCN¥393.5mCN¥199.1mCN¥2.33bnCN¥931.4m
DebtCN¥16.1mCN¥135.8mCN¥141.9mCN¥155.3mCN¥52.1mCN¥46.9mCN¥62.4m
Shareholders' equity−CN¥341.9m−CN¥474.5m−CN¥39.8mCN¥308.6mCN¥693.4m−CN¥1.75bnCN¥3.50bn
Shares outstanding482m425m424m424m115m69m564m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2014
Cash from operations−CN¥38.2m−CN¥104.7m−CN¥278.2m−CN¥281.0m−CN¥587.1m−CN¥151.6m—
Capital spending−CN¥6,000−CN¥89,786−CN¥40.9m−CN¥34.8m−CN¥5.3m−CN¥153.5m−CN¥10.1m
Free cash flow−CN¥38.2m−CN¥104.8m−CN¥319.1m−CN¥315.8m−CN¥592.4m−CN¥305.1m—

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥14.0mCN¥14.0mCN¥13.9mCN¥13.9mCN¥11.1mCN¥11.1mCN¥17.2mCN¥20.2m
Gross profitCN¥9.3mCN¥9.3mCN¥10.6mCN¥10.6mCN¥7.7mCN¥7.7mCN¥10.6mCN¥12.4m
Operating income−CN¥24.0m−CN¥24.0m−CN¥25.4m−CN¥25.4m−CN¥20.9m−CN¥20.9m−CN¥51.8m−CN¥60.6m
Net income−CN¥18.5m−CN¥18.5m−CN¥22.2m−CN¥22.2mCN¥29.6mCN¥29.6m−CN¥83.5m−CN¥97.7m
Diluted earnings per share-0.03-0.03-0.05-0.050.060.06-0.20-0.23
Cash from operations——−CN¥14.0m−CN¥14.0m−CN¥4.0m−CN¥4.0m−CN¥6.0m−CN¥7.0m
Total assetsCN¥192.4mCN¥192.4mCN¥165.4mCN¥165.4mCN¥105.5mCN¥105.5mCN¥99.9mCN¥116.8m
Cash and short-term investmentsCN¥88.1mCN¥88.1mCN¥66.6mCN¥66.6mCN¥2.0mCN¥2.0mCN¥9.0mCN¥10.5m
DebtCN¥19.7mCN¥19.7mCN¥15.9mCN¥7.9mCN¥35.0mCN¥26.5mCN¥116.1mCN¥27.1m
Shareholders' equity−CN¥195.9m−CN¥195.9m−CN¥341.8m−CN¥341.8m−CN¥409.1m−CN¥409.1m−CN¥405.7m−CN¥474.5m

Financial ratios

Data as of 3 Nov 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin73.1%63.8%62.4%61.9%60.3%57.2%
Operating margin-185.5%-400.1%-359.6%-603.5%-3446.4%-7000.1%
Net margin29.6%-520.1%-368.3%-612.2%-3456.3%-7031.6%
Return on equity-4.3%93.3%952.1%-156.7%-155.3%48.5%
Return on assets9.0%-378.9%-95.8%-68.9%-120.7%-144.3%
Free cash flow yield-4.7%-17.2%-33.5%-34.8%-303.1%1.6%
Revenue growth-41.3%-17.3%30.3%153.4%159.0%719.1%
Earnings growth-103.3%16.8%-21.6%-55.1%27.3%288.7%
Current ratio0.24x0.09x0.64x1.82x4.37x3.62x
Debt to equity-0.05x-0.09x-1.04x0.16x0.06x-1.26x
Equity ratio-206.6%-406.2%-10.1%44.0%77.7%-297.7%
Interest coverage-42.67x-39.67x-41.34x-69.45x-348.79x-221.99x
R&D as a share of sales90.1%295.8%250.0%394.0%1372.4%911.3%
Buybacks as a share of market value-13.5%-0.1%-0.1%-269.2%-67.3%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-9.5%33.0%1.7%
Operating income-39.1%-35.7%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin67.6%64.5%63.8%—
Operating margin-312.7%-396.1%-790.5%—
Net margin-296.3%-394.3%-915.4%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings71.3-0.1-1.0-2.2-0.8
Price to sales21.10.73.513.329.2

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.